 This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin in patients with previously untreated advanced non-squamous non-small cell lung cancer nsNSCLC to demonstrate clinical equivalence of BAT1706 and EU Avastin. 